


# Blue Coast Research Center

## CURRICULUM VITAE

<b>SIGNATURE:</b>		<b>DATE:</b>	4/21/2021
<b>NAME:</b>	DAVID SPIEGEL, M.D.	<b>DATE UPDATED:</b>	April 2021
<b>TITLE:</b>	Sub-Investigator		

**RESEARCH SITE NAME/ ADDRESS:**

<p><b>Main Office:</b></p> <p>Blue Coast Research Center 2067 W. Vista Way, #225 Vista, CA 92083</p>	<p>Office: (760) 630-2550 Email: David.spiegel@bluecoastcardiology.com</p>
--	--

**EDUCATION/TRAINING:**

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Naval Hospital, San Diego, CA	Fellowship	1982-1984	Cardiology
Naval Hospital, San Diego, CA	Residency	1980-1982	Medicine
Naval Hospital, San Diego, CA	Internship	1978-1979	Internal Medicine
University of Colorado School of Medicine, Denver, CO	M.D.	1978	Medicine
Oberlin College, Oberlin, OH	B.A.	1974	Physical Chemistry

**POSITIONS AND EMPLOYMENT:**

2021- Present	Sub-Investigator, Blue Coast Research Center, Vista, CA
2015-2021	Sub-Investigator, Blue Coast Cardiology, Vista, CA
1990 - 1993	Director CCU/ICU, Tri-City Medical Center, Oceanside, CA
1990 - Present	Director Cardiac Cath Lab, Tri-City Medical Center, Oceanside, CA

1987-1996	Clinical Instructor, UCSD Medical School, San Diego, CA
1988 - Present	Staff Cardiologist, Tri City Medical Center, Oceanside, CA Cardiologist, Private Practice, Vista, CA
1988-1992	Cardiologist, Mission Park Medical Clinic, Oceanside, CA
1986-1988	Staff Cardiologist and Cath Lab Director, Naval Hospital, San Diego, CA
1984-1986	Staff Cardiologist and CCU Director, Naval Hospital, Bremerton, WA
1979-1980	Medical Officer, 12th Marines, Okinawa, Japan

### **CLINICAL RESEARCH EXPERIENCE:**

COORDINATE – Diabetes: Phase 4, Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes

ImPediMed: Home-Based Fluid Status Monitoring in Heart Failure Patients Recently Hospitalized for Acute Heart Failure.

EPHESUS: A Double Blind; Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Eplerenone in Patients with Heart Failure Following Acute Myocardial Infarction.

CURE- A Phase III Randomized, Double Blind, Parallel Group Clinical Trial of Clopidogrel Versus Placebo in Patients with an Acute Coronary Syndrome (Unstable Angina or Myocardial Infarction without ST Segment Elevation

ASSENT 3: A phase IIIb, randomized, open label trial with 3 parallel groups: full dose TNK-tPA together with heparin sodium; full dose TNK-tPA together with enoxaparin; and half dose TNK- tPA together with abciximab and heparin sodium in patients with acute myocardial infarction

AMP-579-204b: A Randomized, Double Blind, Placebo- Controlled, Dose-Escalation Study to Evaluate the Pharmacodynamic Response, Safety and Pharmacokinetic Profile of RPR 100579 Administered as a Continuous Infusion Plus Intravenous Loading Dose in Patients Undergoing Cardiac Catheterization with or without Percutaneous Coronary Intervention

FESTIVAL: A Phase 2A Safety and Pharmacology Study of an Investigational Medication in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty (postponed until Phase 2B)

A Double-Blind, Placebo-Controlled, Multicenter Study for a New Investigational Medication in Prevention Of Myocardial Reperfusion Injury in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty (CALYPSO)

AMISTAD II: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Adenosine (Pallocor)

VALIANT Trial: Multinational, Multicenter, Double Blind, Randomized, Active Controlled, Parallel Group Study Comparing the Efficacy and Safety of Long-term Treatment with Valsartan, Captopril and their Combination in High Risk Patients After Myocardial Infarction

OPUS - TIMI 16: A Phase 3 International; Randomized, Double - Blind, Placebo - Controlled Trial Evaluation the Efficacy and Safety of a new Oral Glycoprotein 2B3A Platelet Inhibitor in Patients with Unstable Coronary Syndromes

A Phase II, Randomized, Open-Label Parallel Group, Multi Center International Trial of the Safety of a New Thrombolytic Agent in Acute Myocardial Infarction

A Dose-finding Study with a New Investigational Medication- Versus Heparin in Patient with Acute Myocardial Infarction. P.R.I.M.E. (Promotion of Reperfusion by Inhibition of Thrombin During Myocardial Infarction Evolution)

An Angiographic Assessment of the Efficacy and Safety of Front - Loaded, and Bolus Regimens of Activase (Alteplase, recombinant) for the Treatment of Acute Myocardial Infarction

Global Utilization of Streptokinase and tissue – Plasminogen Activator for use of Occluded Coronary Arteries